Inhibition of EZH2 activity is proposed to inhibit tumor growth in non-Hodgkin's lymphoma via inducing the expression of BLIMP1 (a tumor suppressor) [8]. This evidence concerns the gene PRDM1 and non-Hodgkin lymphoma.